Apeloa Pharmaceutical Co

Apeloa Pharmaceutical Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Apeloa Pharmaceutical Co (000739.SZ) as of Oct 22, 2026 is 7.14 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 9.52 % — a change of -25.07% (lower).

EBIT/Assets

7.14 %

YoY

-25.07%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Apeloa Pharmaceutical Co is 2025 7.14 % . Operating Income to Assets Ratio (EBIT/Assets) of Apeloa Pharmaceutical Co was 2024 9.52 % . It decreases by -25.07% lower compared to the previous year.

The Apeloa Pharmaceutical Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
8.53 CNY
Jan 1, 2019
9.88 CNY
Jan 1, 2020
12.94 CNY
Jan 1, 2021
12.38 CNY
Jan 1, 2022
8.42 CNY
Jan 1, 2023
9.56 CNY
Jan 1, 2024
9.52 CNY
Jan 1, 2025
7.14 CNY
The Apeloa Pharmaceutical Co EBIT/Assets history
YEAREBIT/AssetsYoY
7.14 %-25.07%
9.52 %-0.36%
9.56 %+13.56%
8.42 %-32.00%
12.38 %-4.35%
12.94 %+31.01%
9.88 %+15.80%
8.53 %+30.11%
6.55 %+33.96%
4.89 %+30.47%
3.75 %-44.66%
6.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apeloa Pharmaceutical Co Stock analysis

What does Apeloa Pharmaceutical Co do? Apeloa Pharmaceutical Co., Ltd. generates revenue through the research, development, and production of active pharmaceutical ingredient (API) intermediates, contract development and production services (CDMO), and preparations. The company’s main products include bulk drugs, intermediates, chemical preparations, and Chinese traditional medicine preparations such as ubenimex capsules, cefixime, and amantadine. These products are sold to both domestic and overseas markets, with the company distributing its offerings across these segments. The firm’s business model focuses on serving pharmaceutical manufacturers and healthcare providers through its comprehensive range of API intermediates and finished preparations. The company’s revenue streams are derived from the sale of bulk drugs, intermediates, and chemical preparations, alongside its Chinese traditional medicine preparations like ubenimex capsules and cefixime. These products are targeted at pharmaceutical manufacturers seeking API intermediates and finished drug formulations. Apeloa Pharmaceutical serves both domestic and international clients, with its products distributed in both markets. The company’s CDMO services further support clients in the development and production of pharmaceutical products. Apeloa Pharmaceutical’s core business involves the production and sale of API intermediates, bulk drugs, and various preparations, including traditional Chinese medicine products. The company’s main customers are pharmaceutical manufacturers and healthcare providers who require intermediates for drug manufacturing and finished preparations for market distribution. Its domestic and overseas market presence ensures a diversified revenue base, with products like ubenimex capsules and amantadine contributing to its product portfolio. Apeloa Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apeloa Pharmaceutical Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Apeloa Pharmaceutical Co is 7.14 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Apeloa Pharmaceutical Co changed from 9.52 % to 7.14 %, representing a -25.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Apeloa Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Apeloa Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Apeloa Pharmaceutical Co

All Key Metrics — Apeloa Pharmaceutical Co